CD8A and neoplasm: The glycosylated‐PEG–oHSV mitigates the immunosuppressive tumor microenvironment by augmenting the infiltration of CD8+ T cells and NK cells, stimulating the secretion of antitumor cytokines, ultimately impeding HCC progression [607].